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Introduction: Fungal myositis is very uncommon, even in patients who are immunocompromised. Because of its
rarity and a lack of clinical experience, no consensus has been reached about the best means of treating fungal
myositis. To the best of our knowledge this is the first description of the treatment of fungal myositis with
simultaneous intravenous and intra-lesional itraconazole.
Case presentation: A 35-year-old Chinese woman with acute myelomonocytic leukemia developed Candida krusei
fungemia and fungal myositis in the right biceps brachii after chemotherapy. A course of intravenous itraconazole
and subsequently intravenous voriconazole was initiated and her blood cultures became sterile; however, our
patient remained febrile and the myositis did not resolve. Intravenous itraconazole was restarted simultaneously
with low-dose intra-lesional itraconazole. The pyrexia settled after 48 hours and within 10 days the lesion could be
seen to be resolving. After the course of intravenous and intra-lesional anti-fungals was complete, oral itraconazole
was administered as maintenance therapy.
Conclusions: To the best of our knowledge this is the first case in which fungal myositis was successfully treated
with intravenous and intra-lesional itraconazole in a patient with acute myelomonocytic leukemia. The efficacy and
safety of locally-administered itraconazole to treat intractable soft tissue infections requires further evaluation.
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There has been a steady increase in the frequency of op-
portunistic invasive fungal infections (IFIs) in patients
who are immunocompromised, mostly affecting the
broncho-pulmonary tract [1]. Even so, fungal myositis,
an infection of skeletal muscle, is rare. Regardless, sev-
eral cases of fungal myositis caused by Candida, Asper-
gillus and Cryptococcus have been reported in patients
who are immunocompromised [2-5]. As it is rare, indi-
vidual clinicians have rarely seen more than a handful of
cases and therefore no evidence-based treatment guide-
lines have been established beyond the prompt systemic
administration of effective anti-fungal agents. We report
a case in which fungal myositis was treated effectively
with intra-lesional and intravenous itraconazole in a
woman with acute myelomonocytic leukemia.* Correspondence: yaorx828@163.com
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A 35-year-old, 52kg Chinese woman with acute
myelomonocytic leukemia (M4) was admitted to our
hospital with fever. Our patient had been diagnosed as
having leukemia seven months previously and had re-
ceived only three cycles of standard induction chemo-
therapy (cytarabine 100mg/m2 on days one to seven and
with idarubicin 10mg/m2 on days one to three) due to
difficulty in paying for the treatment. At the time of her
admission she was initially treated with broad-spectrum
antibiotics (cefoperazone-sulbactam and levofloxacin).
The results of a physical examination revealed superfi-
cial multiple lymphadenectasis, and our patient’s general
condition was good. A full blood count revealed a neutro-
phil count of 940 cells/mm3. Urine analysis, a computed
tomography (CT) scan of the chest and abdominal ultra-
sonography results were normal. Blood, urine and stool
cultures were also negative. Bone marrow cytomorphology
showed that monoblasts and promonocytes comprised
48.6 percent of non-erythroid cells. Subsequently, our pa-
tient received fludarabine, cytarabine, and granulocyte-. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 2 Ultrasonography of the right biceps brachii showed a
hypo-echoic lesion within the muscle in which blood supply
could be detected by color Doppler flow imaging.
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therapy (cytarabine 1g/m2 on days one to five, with
fludarabine 25mg/m2 also on days one to five). After five
days of chemotherapy, the neutrophil count had fallen to
150 cells/mm3 so she was treated with granulocyte-
macrophage colony-stimulating factor. At day 7, high pyr-
exia was evident, but the results of a repeat chest CT scan
was normal and blood cultures were sterile. Empiric
therapy with imipenem/cilastatin and vancomycin was
started. On day 13, high pyrexia recurred and subse-
quently two separate peripheral venous blood specimens
grew Candida krusei, which was sensitive to itraconazole,
voriconazole and amphotericin B, but resistant to flucona-
zole and 5-fluorouracil. Intravenous itraconazole (400mg
loading dose for the first two days followed by 200mg
daily) was started (Figure 1). On the 15th day our patient
reported right upper arm pain with signs of erythema,
swelling and hyperalgesia; ultrasonography revealed a
hypo-echoic lesion within the right biceps brachii,
19×55mm in size, in which blood flow could be detected
by color Doppler flow imaging (Figure 2). By day 17, her
temperature had gone down to 38.0 to 38.5°C, but at day
25 a low grade fever persisted and the biceps lesion had
not changed, although the blood cultures no longer grew
Candida. Histopathological examination of a biopsy speci-
men from the lesion showed dense fungal spores, no hy-
phae, but evidence of focal myocyte necrosis and
inflammatory cell infiltration (Figure 3a-c). Spore morph-
ology, as demonstrated by periodic acid-Schiff (PAS) and
Grocott’s methenamine silver (GMS) staining, was charac-
teristic of fungi. The muscle specimen was inoculated on
medium and the culture grew C. krusei, confirming the
histopathological diagnosis. Anti-fungal susceptibility tests
found sensitivities similar to that of the blood culture. Con-
sequently, intravenous itraconazole was substituted with
voriconazole (200mg twice daily) for seven days (days 28 to
34), as antibiotics were gradually discontinued. However,
the pyrexia persisted and the lesion had not diminished in
size. Our patient declined the offer of excision, soFigure 1 Thermometric evolution and anti-fungal drug therapy.intravenous itraconazole was initiated once again and the
decision was made to inject itraconazole 5mg daily into the
lesion. Her fever gradually subsided within 48 hours of
commencing intra-lesional itraconazole. Then, 10 days
later, a further ultrasound scan demonstrated almost
complete resolution of the lesion. Once the neutropenia
had resolved, the intravenous and intra-lesional itraco-
nazole were discontinued in favor of oral maintenance
therapy with itraconazole 200mg twice daily. A follow-up
ultrasound scan one month later showed complete reso-
lution of the muscle lesion.
Discussion
IFI is a recognized consequence of an immunocomprom-
ised state, but there are many possible underlying causes.
These include neutropenia, exposure to high-dose cor-
ticosteroids, the presence of intravascular catheters and
prolonged exposure to broad-spectrum antibiotics. Fluda-
rabine also impairs cell-mediated immunity and can contrib-
ute to the initiation of IFIs. To the best of our knowledge
this is the first case report of a fungal myositis arising in a
patient who was neutropenic with acute myelomo-
nocytic leukemia during fludarabine-based chemotherapy in
China. Most infectious myositis is bacterial in etiology, with
Staphylococcus aureus being the most common causative
organism. Fungal myositis, although rare, has been described
and is a recognized complication of systemic mycosis
[2,6-8]. The Candida species most often implicated in
fungal myositis include Candida tropicalis, C. krusei and
Candida albicans [6-8]. The potential routes of infection are
generally considered to be hematogenous dissemination, iat-
rogenic or traumatic with direct inoculation of spores. In
our patient’s case, as they had no history of trauma or long-
term indwelling catheters, the infection is most likely to have
resulted from hematogenous dissemination.
Figure 3 A histopathological analysis of muscle tissue showed focal necrosis with inflammatory cell infiltration and diffuse fungal
spores among the muscle cells. (a) hematoxylin and eosin stain, ×100; (b) Grocott’s methenamine silver stain, ×100; (c) periodic acid-Schiff
stain, ×400.
Lin et al. Journal of Medical Case Reports 2013, 7:132 Page 3 of 4
http://www.jmedicalcasereports.com/content/7/1/132Apart from the treatment of aspergilloma in fibro-
cavitary lung disease with intra-cavitary amphotericin B
[9-11] and Candida joint infection with intra-articular
amphotericin B [12,13], the local administration of anti-
fungal drugs for IFIs is uncommon. Itraconazole was reg-
istered for use in 1991 and is widely used to treat several
forms of mycosis; however, to the best of our knowledge
this is the first case report of the use of intra-lesional
itraconazole for fungal myositis.
Pharmacokinetic studies have shown that itraconazole
is extensively taken up by the tissues in normal adults
and therapeutic levels of itraconazole are maintained
many times higher in some infected tissues than plasma.
Regardless, in our patient’s case she remained febrile and
the myositis persisted despite 22 days of intravenous
itraconazole and voriconazole. It is not clear why thera-
peutic levels sufficient to treat the myositis successfully
were not attained in our patient’s case, although it may
be that surrounding ischemic and necrotic muscle re-
duced tissue penetration. We believe that in our patient’s
case the systemic treatment alone was inadequate and
hypothesize that the use of the combination of intraven-
ous itraconazole and low-dose intra-lesional itraconazole
accounted for our patient’s clinical improvement. How-
ever, the influence of low-dose intra-lesional itraconazole
in the successful outcome of our patient’s case is not
completely clear. The clinical response observed could
also have been the result of prolonged administration of
intravenous itraconazole in the context of recover-
ing neutropenia and the use of oral maintenance
itraconazole therapy. No side effects were observed
as a result of the intra-lesional administration of
itraconazole.
Our patient’s case shows that intra-lesional treatment
of fungal myositis with itraconazole is safe and feasible.
Future trials should investigate the optimum intra-
lesional dose, toxicity and the local application of
itraconazole to other tissues.Conclusions
We report what is, to the best of our knowledge, the first
case of fungal myositis successfully treated with intra-
venous and intra-lesional itraconazole in a patient with
acute myelomonocytic leukemia. The efficacy and safety
of the local administration of itraconazole for infected
soft tissues requires further evaluation.
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